Abstract
Numerous studies, since the late 1970s, have highlighted the role of vasoactive intestinal peptide (VIP) in the immune system of mammals. Importantly, these studies have show that VIP has an inhibitory effect on the production and action of many different inflammatory mediators and many studies have now shown the therapeutic potential of VIP in animal models of human disease. This review will briefly discuss the effects of VIP on immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans. The review will also introduce some areas of research which are discussed by contributing authors within this special edition of EMIDDT.
| Original language | English |
|---|---|
| Pages (from-to) | 303-307 |
| Number of pages | 5 |
| Journal | Endocrine, Metabolic and Immune Disorders - Drug Targets |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| Publication status | Print publication - 3 Dec 2012 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Vasoactive intestinal peptide (VIP): Historic perspective and future potential'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver